Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
COMMENTARY
CASE-J Flutter: Doesn’t Blopress Ad Overemphasize Its Benefits on Diabetes?
Over the past month, a new suspicion has hit Japan’s pharmaceutical industry – one involving the investigator-initiated CASE-J trial comparing Takeda Pharmaceutical’s angiotensin receptor blocker Blopress (candesartan) and the calcium channel blocker amlodipine. Takeda President Yasuchika Hasegawa has issued an…
To read the full story
Related Article
COMMENTARY
- Supply Woes Plague All 7 New Biosimilar Ingredients Listed since 2023
November 16, 2026
- Japan Drug Wholesalers Caught in Multiple Dilemmas as Price Gap Narrows
November 10, 2026
- Deeper CEA Price Cuts Demand More Than a “Certain Degree of Validity”
November 2, 2026
- Alzheimer’s Pipeline Looks Past Amyloid to Earlier Intervention, Tau Targets
October 28, 2026
- Lp(a) Drugs Face Next Test in Quest to Cut Cardiovascular Risk
October 19, 2026





